"I am very excited to join such a devoted, innovative and accomplished team and feel privileged to be given the opportunity by the Board to lead Theranostics Health, a company at the forefront of shaping a new paradigm of healthcare and disease management," Dr Chen noted. "We strongly believe that Danong's impressive scientific and business credentials combined with her proven management and leadership skills will enable Theranostics Health to achieve its true potential in the years ahead," said Dr. James Cooper, the Chairman of the Board.
About Theranostics Health
Theranostics Health is a privately held company founded in 2006. Its core technology is the breakthrough Reverse Phase Protein Microarray (RPMA) combined with Laser Capture Microdissection (LCM). The technology measures the activity of a large number of biomarkers, enabling pharmaceutical companies to accurately profile their drug candidates to facilitate efficient and effective drug development. More importantly, it enables physicians to tailor optimized therapies to their patients based on the biomarker profile of each individual patient, providing safer and more effective therapies. The technology, invented by the company's co-founders Drs. Emanuel Petricoin and Lance Liotta, was first published by them in 2001, has been featured in over 50 peer-reviewed publications and 20 scientific presentations within the past 2 years, and was successfully used in NCI-sponsored clinical trials. Currently, Theranostics Health is working with 5 of the top 10 global pharmaceutical companies in their drug R&D efforts. The company closed its seed financing of $5 million in 2007 and generated revenue in its first year of operations. For more information please email info@theranosticshealth.com or visit http://www.theranosticshealth.com.
Source: Theranostics Health, LLC
